PTX3在非酒精性脂肪肝患者血清中的表达及与肝纤维化评分的相关性

肝脏 ›› 2019, Vol. 24 ›› Issue (2): 175-177.

PTX3在非酒精性脂肪肝患者血清中的表达及与肝纤维化评分的相关性

汤群, 欧强

200235 上海上海市第八人民医院

收稿日期:2018-05-09 发布日期:2020-04-10
通讯作者: 欧强,Email:ouqiang76@163.com
基金资助:
上海市卫生计生委面上课题(201640224);上海市徐汇区系统人才培养计划配套课题(BY201607)

Received:2018-05-09 Published:2020-04-10

摘要/Abstract

摘要： 目的观察非酒精性脂肪性肝病(NAFLD)患者血清正五聚体蛋白-3(PTX3)的表达及与非酒精性脂肪性肝纤维化评分(NAFLDFS)的相关性。方法共纳入73例NAFLD患者,选取同期70名健康体检者作为健康对照组。采用ELISA法检测受试者血清PTX3水平。结果 NAFLD患者组体质指数(BMI)、腰围、ALT、AST、胆固醇(TC)、甘油三酯(TG)、PTX3、空腹血糖(FBG)、胰岛素抵抗指数(HOMA-IR)均显著高于健康对照组,差异有统计学意义(P<0.01)。NAFLD患者肝纤维化危险组PTX3、FBG水平明显高于无肝纤维化NAFLD患者组,差异有统计学意义(P<0.05)。Pearson相关性分析结果显示,PTX3与NAFLDFS呈显著正相关(r=0.429,P<0.01)。结论 PTX3在NAFLD患者血清中存在高表达,并与肝纤维化密切相关。PTX3能在一定程度上反映NAFLD相关肝纤维化严重程度。

关键词: 非酒精性脂肪性肝病, PTX3, 相关性, 肝纤维化评分

汤群, 欧强. PTX3在非酒精性脂肪肝患者血清中的表达及与肝纤维化评分的相关性[J]. 肝脏, 2019, 24(2): 175-177.

参考文献

[1] Rinella ME.Nonalcoholic fatty liver disease:a systematic review. JAMA, 2015,313:2263-2273.
[2] Diehl AM,Day C.Cause,pathogenesis,and treatment of nonalcoholic Steatohepatitis. N Engl J Med,2017,377:2063-2072.
[3] Yoneda M, Uchiyama T, Kato S,et al.Plasma Pentraxin3 is a Novel Marker for Nonalcoholic Steatohepatitis (NASH).BMC Gastroenterol, 2008, 8:53.
[4] Inforzato A,Reading PC,Barbati E,et al.The“sweet”side of a long Pentraxin:how glysocylation affects PTX3 functions in innate immunity and inflammation.Front Immunol,2012,3:407.
[5] 中华医学会肝病学分会脂肪肝和酒精性肝病学组.非酒精性脂肪性肝病诊疗指南(2018年更新版).实用肝脏病杂志,2018,21:177-186.
[6] Musso G,Gambino R,Cassader M,et a1.Meta-analysis:natural history of non-alcoholic fatty liver disease(NAFLD)and diagnostic accuracy of non-invasive tests for liver disease severity.Ann Med,2011,43:617-649.
[7] Vilahur G, Badimon L.Biological actions of pentraxins.Vascul Pharmacol.?2015, 73:38-44.
[8] Sawada H, Naito Y, Oboshi M,et al.Increment of pentraxin3 expression in abdominal aortic aneurysm.Int J Cardiol,2015, 195:281-282.
[9] Younossi ZM,Koenig AB,Abdelatif D,et al. Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence,incidence,and outcomes. Hepatology,2016,64:73-84.
[10] Rombout K,Marra F.Molecular mechanisms of hepatic fibrosis in non-alcoholic steatohepatitis.Dig Dis,2010,28:229-235.
[11] Gentil C, Le Jan S, Philippe J, et al. Is oxygen a key factor in the lipodystrophy phenotype.Lipids Health Dis,2006,5:27.
[12] 邓银芝,黄铁军,张明哲,等.非酒精性脂肪肝病患者血清PTX3 水平与胰岛素抵抗以及氧化应激相关分析.中国肝脏病杂志(电子版),2015,7:101-105.
[13] Angulo P,Hui JM,Marchesini G,et al.The NAFLD fibrosis score:a noninvasive system that identifies liver fibrosis in patients with NAFLD.Hepatology,2007,45:846-854.
[14] Wong VW,Wong GL,Chim AM,et al.Validation of the NAFLD fibrosis score in a Chinese population with low prevalence of advanced fibrosis.Am J Gastroenterol, 2008,103:1682-1688.
[15] Boga S, Koksal AR, Alkim H,et al.Plasma Pentraxin 3 Differentiates Nonalcoholic Steatohepatitis (NASH) from Non-NASH. Metab Syndr Relat Disord,2015,13:393-399.